Wall Street regained some momentum on Friday, after the AI trade came under pressure on Thursday.

The S&P 500 (SP500) closed up 0.59%, the Dow jumped 0.83%, and the Nasdaq Composite advanced 0.6%.

The S&P 500 Health Care Sector Index also gained 2.39% for the week.

The top S&P 500 healthcare gainers and losers for the past week are as follows:

Top Gainers:

Moderna +18.36%

Humana  +11.18%

Veeva Systems +8.31%

Intuitive Surgical +8.17%

Zoetis  +7.29%

Top Losers:

The Cooper Companies -4.46%

Bristol-Myers Squibb -3.32%

Incyte -2.18%

DexCom -1.46%

Henry Schein -1.02%

Here are some of the important healthcare stories from this week:

Novavax, Moderna cool as WHO downplays plague-related death in Russia

Novavax , Moderna , and other pandemic-era favorites traded flat in the premarket on Tuesday after the WHO said that Russian officials have traced all the people in contact with the plague research lab employee who died of pneumonia of an “unknown” cause last week.

"All of the patients' contacts have been ​reportedly been identified ​and are being monitored for illness, ‌and ⁠none to date have shown symptoms of illness," Reuters reported, quoting WHO ​spokesperson Christian ​Lindmeier.

Lindmeier said that Russian authorities are investigating whether pneumonic plague ​caused the female laboratory technician’s death. However, the Russian side has not yet officially responded to the WHO request for information, the spokesperson added.

Novavax closed 20% higher, and Moderna added 7% on Monday after Rospotrebnadzor, a Russian agency tasked with handling infectious diseases, reported the death of the 28-year-old worker at the Irkutsk Research Anti-Plague Institute of Siberia.

Other notable gainers included messenger RNA drug developer Arcturus Therapeutics and biodefense company Emergent BioSolutions , which, alongside Novavax and Moderna , were among clear favorites during the COVID-19 pandemic.

Trump: Becton Dickinson agrees to invest $3B in US manufacturing, including $1B+ in Nebraska

U.S. medical technology company Becton Dickinson agreed to invest $3B to bring the manufacturing of essential medical products to the United States, President Donald Trump said Monday in a post on Truth Social.

BD will invest more than $1B ⁠in Nebraska to ramp up production of numerous products, ​including needles ​made ⁠with American steel, Trump noted.

BD said it plans to invest $19 billion in the U.S. over several years across capital, operations, and supply-chain initiatives, including $3 billion to expand manufacturing at strategic sites nationwide. The company expects to increase domestic production of essential medical consumables by about 5 billion units annually, raising the share of such products supplied from within the U.S. to roughly 80%, according to a statement.

CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases

CSL and Alentis Therapeutics have entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver, and other diseases.

Under the agreement, CSL will arrange an initial payment of $355M to Alentis, which is also eligible for up to $1.2B in commercial milestone payments. The companies will share global profits 55% to CSL and 45% to Alentis once the drug is commercialized.

CSL will fund Phase 2 and planned Phase 3 studies of lixudebart in AAV-RPGN while advancing Phase 2 programs in FSGS and PSC.

Lixudebart is currently being evaluated in the Phase 2 RENAL trial for AAV-RPGN, a rare autoimmune disease that can cause rapid kidney function loss and irreversible kidney damage.

Viatris to buy Pacira BioSciences in $1.65B deal

Viatris and Pacira BioSciences said they entered into a definitive agreement under which Viatris will acquire all outstanding shares of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65B.

The transaction is expected to close by the end of 2026.

Upon completion of the transaction, Pacira will become a wholly owned subsidiary of Viatris, and Pacira's common stock will no longer be listed for trading on the Nasdaq Global Select Market.

The deal advances Viatris’ innovative medicines strategy, adding two patent-protected pain therapies- EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain.

Pacira generated approximately $746M in total revenue and ~$177M in adjusted EBITDA during the last twelve months ended June 30, 2026.